Category Archives: Biotechnology

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) will unveil findings from a report on the role of Intellectual Property Rights (IPRs) in encouraging upstream R&D and downstream commercialization in biotechnology at the 2012 BIO International Convention in Boston, Mass.

The report, titled Taking Stock: the Gains of Global Biotechnology Research from IPRs, will bring together experts to discuss how IPRs have affected innovation and the development of new biotechnologies and whether they contribute to growth in partnerships and other models of collaboration between biotechnology R&D actors such as universities, small and medium sized entities (SMEs) and pharmaceutical manufacturers.

Rachel Chu, Senior Consultant, Pugatch Consilium

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW,a multiblog platform and monthly newsletterthat aims to create an online biotech community where thethe industrycan connect to discuss the latest news. Subscribe to BIOtechNOW.

For more information: Visit http://www.bio.org Follow us on Twitter @IAmBiotech Join us on LinkedIn/MyBio Become a fan at facebook.com/IAmBiotech

Link:
BIO to Release Intellectual Property Rights Report at 2012 BIO International Convention

TORONTO, ONTARIO--(Marketwire - June 13, 2012) - Cynapsus Therapeutics (CTH.V) today announced that an article discussing its APL-130277 drug candidate will be published in the July 2012 Issue of the Journal of Commercial Biotechnology. The article titled "Creating systemic oral transmucosal drug delivery strategies: Case study of APL-130277" was co-authored by Anthony Giovinazzo, President and CEO of Cynapsus, Nathan Bryson, Chief Scientific Officer of Cynapsus, and Timothy Tankosic, Managing Director of Aqua Partners, LLC.

The July 2012 issue of the Journal of Commercial Biotechnology will be published on July 1, 2012 and distributed earlier at the BIO International Convention (http://convention.bio.org/) being held in Boston, MA, USA, from June 18 to 21, 2012.

The article broadly addresses the strategic application of systemic oral transmucosal (i.e., sublingual and buccal) drug delivery. The article also provides a specific discussion of the scientific, clinical and commercial considerations driving APL-130277, an easy-to-administer, fast-acting, oral reformulation of an approved drug, apomorphine, being developed to rescue Parkinson's patients from "off" episodes. The principal advantages the oral transmucosal route and APL-130277 include: circumvention of first-pass hepatic metabolism in the gut, rapid onset of action, easy access via the oral cavity, easy administration for patients with dysphagia, and a high level of patient acceptance.

The full text version of the article is available at http://commercialbiotechnology.com (Subscription Required), or by contacting Anthony Giovinazzo at ajg@cynapsus.ca.

About Cynapsus Therapeutics

Cynapsus is a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. Over one million people in the United States and an estimated 5 million people globally suffer from Parkinson's disease. Parkinson's disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. It is estimated that between 25 percent and 50 percent of patients experience off episodes in which they have impaired movement or speaking capabilities. Current medications only control the disease's symptoms, and most drugs become less effective over time as the disease progresses.

Cynapsus' lead drug candidate, APL-130277, is an easy-to-administer, fast-acting, oral reformulation of an approved drug, apomorphine, used to rescue patients from off episodes. Cynapsus is focused on rapidly maximizing the value of APL-130277 by completing pivotal studies in advance of a New Drug Application expected to be submitted in 2014. Cynapsus anticipates out-licensing to an appropriate pharmaceutical partner before such an application is submitted.

More information about Cynapsus (CTH.V) is available at http://www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval (SEDAR) at http://www.sedar.com.

About The Journal of Commercial Biotechnology

The Journal of Commercial Biotechnology is the definitive international quarterly publication for bioscience business professionals. The Journal is designed specifically for those professionals who need to enhance their knowledge of biotechnology business strategy and management, improve and advance their product development or want to keep up-to-date with current issues and industry trends. Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as Management, Policy, Finance, Law, Regulation and Bioethics.

See the article here:
Cynapsus Therapeutics has Article Published in Journal of Commercial Biotechnology

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) is pleased to announce the BIO International Leadership Award winner for the 2012 BIO International Convention is the Rt Honourable David Willetts MP, Minister for Universities and Science, United Kingdom.

It is a real honor to be presented with the BIO International Leadership Award and to have the UKs work to support the life sciences industry recognised internationally, said Minister Willetts. Our life sciences sector is world-class but we are not complacent. Its vital we respond to global changes in the industry with more focus on collaboration and more prompt clinical trials. We want to ensure the industry continues to drive growth, foster innovation and attract overseas investment. The 2012 BIO International Convention is a great place to kick-start global collaborations, and we look forward to tracking the success stories of the hundreds of UK delegates at this event.

In his role as Minister of State for Universities and Science, Minister Willetts is responsible for looking across all departmental business at strategic priorities as well as higher education, science and research, life sciences and innovation. He is also responsible forthe Technology Strategy Board, UK Space Agency and the National Measurement Office.

The BIO International Leadership Award is presented to a Premier, Federal Minister or other high-level public official for his or her commitment to advancing biotechnology through policy mechanisms that facilitate and strengthen a country or regions innovation frameworks. The award will be presented on Tuesday, June 19th at the Public Officials Reception from 5:30 7:00 p.m. at the Massachusetts State House in Boston, Mass.

The first Annual International Leadership Award was presented in 2008 to The Honourable Peter Beattie for his efforts during his tenure as Premier of Queensland, Australia. In 2009, the Award was granted to The Honourable Dalton McGuinty, Premier of Ontario, Canada and in 2010, the Award was granted to The Honourable Miguel Sebastin, Spains Minister of Industry, Tourism & Trade.

The BIO Business Forum has grownover thepast eleven years to become theindustry's largest partnering event, hosting a record breaking 21,000+ partnering meetings in 2011. Powered byBIO's One-on-One Partnering System, the Business Forum fosters the opportunity for companies toinitiate business contacts in a friendly environment and schedule meetings prior to theconference. To take advantage of partnering, please visit here.

The BIO Business Forum also hosts over 160 company presentations, which by participating, will allow the Buzz of BIO winners to increase visibility, attract more partners and pitch their company objectives to a global audience representing over sixty countries and various industry investors, research analysts, policy makers and other business development executives.

The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. For registration, conference agenda and exhibitor information, visit 2012 BIO International Convention.

Upcoming BIO Events

Read this article:
2012 BIO International Convention International Leadership Award Winner Announced

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) today co-signed a letter to leaders of the House and Senate sent by nine biofuel trade associations, environmental advocates, and agriculture policy groups expressing strong support for extending and maintaining federal policies that are critical to the ongoing development of advanced biofuels.

Congress made an historic commitment to advanced biofuels in the Energy Independence and Security Act of 2007, as part of a comprehensive strategy to reduce oil dependence, improve national security, and spur economic growth. With gas prices recently spiking to record levels and remaining highly volatile, it is self-evident that the United States needs to develop homegrown alternatives to oil to protect American consumers at the gas pump, the letter states.

The advanced and cellulosic biofuels industry is now in the process of building new plants, innovating at existing production facilities with emerging technologies, and introducing new product streams that will allow the renewable fuels sector to become more profitable, diversified and efficient. Significant investment dollars are being secured with the expectation that Congress will remain committed to advanced biofuels. Rapidly commercializing these technologies will provide substantial oil savings to consumers with far lower environmental impacts than todays fuels, the groups go on to note.

Brent Erickson, executive vice president of BIOs Industrial & Environmental Section added, Because of the RFS, innovative U.S. companies in every corner of the nation have moved as rapidly toward commercialization as possible. These companies are at a critical juncture, with new biorefineries under construction and production coming online at a time when major oil refineries are shutting down production capacity. In order to foster the U.S. lead in innovation, the federal government must continue to support development of the advanced biofuel industry. Private investment in the industry relies on policy stability.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech NOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtech NOW.

Upcoming BIO Events

2012 BIO International Convention June 18-21, 2012 Boston, MA

BIO Business Forum June 18 21, 2012 Boston, MA

More here:
BIO Joins Group of Organizations Asking Congress to Ensure Policy Stability for Advanced Biofuels

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announced today that New Jersey Governor Chris Christie was presented with its 2012 Governor of the Year award in recognition of his leadership and commitment to advancing biotechnology and promoting public health.

Governor Christie received the award in advance of next week's 2012 BIO International Convention in Boston, MA.

I am honored to be recognized by the Biotechnology Industry Organization, said Governor Christie. The key to economic recovery, both in our state and nationally, lies in securing economic growth and job creation in innovative industries such as the biotech sector. I'm proud that New Jersey continues to lead the way in this sector - creating the jobs and technology breakthroughs that improve the quality of life for our citizens and people around the world.

Governor Christie has been an exemplary leader in enhancing New Jerseys stature as one of the nations most vibrant biotech clusters through strong support for policies that benefit a pro-business and pro-biotechnology environment. His funding and support of biotech tax credits is a model for federal legislation that supports critical early-stage capital formation, said Jim Greenwood, President and CEO of BIO. The Governors leadership in this field will continue to benefit his state and region, in terms of jobs and innovation, for years to come.

From the moment he was inaugurated, Governor Christie has been a strong supporter of advancing biotechnology in New Jersey, and BioNJ is pleased to have nominated the Governor for this well deserved award, said Debbie Hart, President of BioNJ. In both word and deed, Governor Christie has worked to help our companies succeed as witnessed by his leadership in supporting the Technology Business Tax Certificate Transfer Program, the doubling of the R&D Tax Credit and naming of BioNJ to run the Life Sciences Talent Network.

Photos available upon request.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Read more here:
New Jersey Governor Chris Christie Presented 2012 BIO Governor of the Year Award

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) will host a special China Day program dedicated to exploring questions about the changing landscape for innovation, healthcare reform, global regulatory trends and discuss the right ways to partner at the 2012 BIO International Convention in Boston, Mass.

The event will feature speakers with decades of experience conducting business in the Chinese life science sector. Panels will cover topics such as Healthcare Innovation in China, Developments in the IP Landscape in China, Global Trends in Biologics Regulations, Chinas Changing Market and Cross-Border Partnering in Biotechnology.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW,a multiblog platform and monthly newsletterthat aims to create an online biotech community where thethe industrycan connect to discuss the latest news. Subscribe to BIOtechNOW.

For more information: Visit http://www.bio.org Follow us on Twitter @IAmBiotech Join us on LinkedIn/MyBio Become a fan at facebook.com/IAmBiotech

The rest is here:
BIO to Host China Day: Biotechnology in the Middle Kingdom: A New Plan, A Renewed Focus, A One Billion Person Promise